Seely Lynn
President and CEO
Seely Lynn has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Aug 25, 2026.
On the most recent filing, Seely Lynn is listed as President and CEO at Lyell Immunopharma, Inc. Inside the rolling window, Seely Lynn reported no open-market purchases and 6 open-market sales totaling $353K in LYEL. The largest disclosed transaction in the window is a sale of 7,455 LYEL shares on Feb 11, 2026, worth $174K.
Companies traded
Other insiders at LYEL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$353K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Seely Lynn made?
Seely Lynn has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Seely Lynn trade?
Seely Lynn has filed SEC Form 4 disclosures for 1 company, including LYEL.
When was Seely Lynn's most recent SEC Form 4 filing?
Seely Lynn's most recent SEC Form 4 filing on Tracefour is dated Aug 25, 2026.
What is Seely Lynn's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Seely Lynn is listed as President and CEO.
What is Seely Lynn's total buy and sell value in the current window?
Inside the rolling retention window, Seely Lynn bought $0 and sold $353K based on SEC Form 4 filings.
What was Seely Lynn's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,455 LYEL shares on 2026-02-11, worth $174K, per SEC Form 4 filings.